Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2021
April 29 2021 - 5:00AM
Novo Nordisk A/S – Total number of voting rights and share capital
in Novo Nordisk A/S as of 29 April 2021
Bagsværd, Denmark,
29 April 2021 – In accordance
with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S
is required to publish the total number of voting rights and the
size of the share capital in Novo Nordisk A/S as per the end of a
month where changes therein have occurred.
Referring to Company Announcement no 27/2021 dated 27 April
2021, please find below a statement regarding the total number of
voting rights and share capital in Novo Nordisk A/S as per 29 April
2021.
|
Number of shares
(of DKK 0.20
each) |
Share capital (nominal
value, DKK) |
Number of votes1 |
A shares |
537,436,000 |
107,487,200 |
107,487,200,000 |
B shares |
1,772,564,000 |
354,512,800 |
35,451,280,000 |
Total |
2,310,000,000 |
462,000,000 |
142,938,480,000 |
1 Each A share of DKK 0.01 carries 10 votes, whereas each B
share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.20
carries 200 votes and each B share of DKK 0.20 (the present
denomination of the company's shares) carries 20 votes. Treasury
shares are included in the table above but voting rights of
treasury shares are suspended at the general meetings of Novo
Nordisk A/S.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079 4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg (US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No 28 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024